Find Academic Supervisors

Staffan Kjelleberg is a Distinguished University Professor at Nanyang Technological University (NTU), Singapore, and Director of the Singapore National Biofilm Consortium (SNBC) and Singapore Centre for Environmental Life Sciences Engineering (SCELSE). He holds previous positions as Scientia Professor at the University of New South Wales (UNSW), Australia, and has led major research initiatives globally. His academic career spans over four decades, with roles including Head of School at UNSW and Professorships at the University of Gothenburg, Sweden. Education: BSc (Chemistry and Biology, 1975), PhD (Microbiology, 1981), and Docent (Microbiology, 1983) from the University of Gothenburg. He has authored over 384 journal papers with significant citations, reflecting his leadership in microbial biofilm research. Research focuses on microbial biofilms and microbiomes, addressing environmental sustainability, public health, and industrial applications. He employs an interdisciplinary approach to study biofilm community dynamics, matrix properties, and translational technologies for biofilm control. Key contributions include discoveries on quorum sensing inhibitors, biofilm dispersal mechanisms, and eDNA roles in biofilm structure. Honours include Fellowships from the Australian and American Academies of Microbiology, Web of Science Highly Cited Researcher status, and Editor roles for 15 international journals. He leads major programs like the Marine Climate Change Science initiative and has co-directed global research centers such as the Centre for Marine Bio-Innovation. Advising and grants: While specific student names are not listed, his extensive leadership in research programs indicates mentorship of numerous scholars. His work bridges fundamental and applied microbiology, impacting environmental and biomedical fields. Labs/Teams: Directs SCELSE and SNBC, co-founded the Centre for Marine Bio-Innovation, and collaborates internationally on biofilm and microbiome research.

• Microbial Biofilms
• Environmental Microbiology
• Antibiofilm Drug Development
• +4 more

Dr. Michael Baym is an Associate Professor of Biomedical Informatics at Harvard Medical School with affiliate appointments in Microbiology and the Laboratory of Systems Pharmacology, and as an Associate Member of the Broad Institute. He leads the Baym Lab, which studies microbial evolutionary genomics and antibiotic resistance through a hybrid of experimental, computational, and theoretical approaches. His research focuses on: Antibiotic Resistance Evolution and practical interventions Mobile Genetic Elements (plasmids, phages, transposons) Computational Genomic Algorithms for big data analysis Synthetic Biology tools and technologies Key recent publications explore phage discovery systems , phylogenetic compression of microbial genomes, and RNA-guided gene drives in plasmids. His work is supported by multiple NIH/NIGMS and NSF grants including a MIRA award. Scientific honors include: Packard Fellowship (2018) Pew Biomedical Scholarship (2020) Sloan Research Fellowship (2020) A. Clifford Barger Excellence in Mentoring Award (2021) SSQBio Mentorship Award (2022) The lab actively trains PhD students and postdoctoral fellows with alumni occupying academic and industry positions globally. Current team members include researchers from interdisciplinary backgrounds working at the intersection of experiment, computation, and theory .

• Microbial Evolutionary Genomics
• Antibiotic Resistance
• Computational Biology
• +7 more

Senior Lecturer Outi Salo-Ahen is affiliated with Åbo Akademi University's Faculty of Natural Sciences and Engineering , Department of Pharmacy. Her research focuses on computational pharmacology, drug design, and pharmaceutical chemistry, particularly targeting chemokine receptors (CCR5/CXCR4) and transient receptor potential channels (TRPA1) for therapeutic applications. Doctor of Pharmacy (2006, University of Kuopio/UEF) MSc in Pharmaceutical Chemistry (2001, UEF) BSc in Pharmacy (1999, UEF) University Pedagogy Modules 1-5 (2012-2015) Her work contributes to UN Sustainable Development Goals through education and pharmaceutical innovation . Recent research trends include: Antimicrobial resistance solutions TRPA1 channel modulation Nanotechnology-enabled drug delivery Multi-target HIV-1 inhibitors 3D printing of biocompatible materials Computational analysis of nucleic acid frameworks She actively supervises doctoral projects, serves on assessment panels, and leads collaborations like Nordic Pharmaceutical Translation and Innovation. Her 60+ publications demonstrate expertise in molecular modeling and drug discovery.

• Pharmaceutical Chemistry
• Molecular Modeling
• Drug Design
• +5 more

Professor Lucy Kimbell is Professor of Contemporary Design Practices at Central Saint Martins, University of the Arts London, where she convenes the Policy Futures Studio. She is Co-Director of the Sustainable Transitions through Democratic Design Doctoral Network funded by the EU Marie Curie programme and serves as Visiting Professor at University of Ulster and Honorary Adjunct Professor at RMIT University. Her work bridges design practice, public policy, and social innovation across multiple international contexts. Professor Kimbell's educational background includes a PhD in Design from Lancaster University (2013), an MA in Computing in Art and Design from Middlesex University (1996), and a B. Engineering in Design and Appropriate Technology from the University of Warwick (1989). Her academic journey reflects a consistent integration of technical, creative, and social perspectives. Kimbell's research focuses on service design, social design, and design for policy, with increasing emphasis on sustainable transitions and democratic innovation. She explores how design methods can address complex societal challenges, particularly through transdisciplinary approaches that connect creative practice with public policy contexts. Her work examines the role of design in government, professional services, and community settings, with particular attention to AI readiness in professional service firms and antimicrobial resistance policy in India. She has pioneered frameworks for measuring design's social and environmental value, notably through the Design Value framework developed with the Design Council. Her recent publications demonstrate a clear trajectory toward understanding design's role in public policy, sustainable transitions, and democratic innovation. The research shows increasing integration of practice-based research methods with policy development, emphasizing transdisciplinary collaboration and the application of design thinking to complex societal challenges. There's a notable focus on developing frameworks for measuring design's social and environmental value and advancing democratic innovation through design practice. Notable recognitions include: AHRC Research Fellow in Policy Lab in the Cabinet Office (2014-15) Principal research fellow at University of Brighton (2013-15) Clark Fellow in Design Leadership at Said Business School, University of Oxford (2005-10) Professor Kimbell supervises transdisciplinary PhD research connecting design with public policy, with six completions to date including four UAL-KCL joint studentships. She examines PhDs internationally and serves on the supervisory board for the PhD in Service Design for Public Sector at Sapienza University, Rome. Her grant portfolio includes major projects funded by EU Marie Curie, AHRC, ESRC, and Creative Europe, totaling millions in research funding for design-led approaches to societal challenges, including the Sustainable Transitions through Democratic Design Doctoral Network (2024-28) and the AHRC Design & Policy Research Network (2022-23). She previously directed UAL's Social Design Institute (2019-2022), which brought together university expertise in design for society through capacity building, joint research, publications, and public events. Her collaborative work extends to knowledge exchange projects with Design Council, Department of Work and Pensions, Northern Ireland Social Care Council, and Bite Back 2030, demonstrating her commitment to applying design thinking to real-world policy and social challenges.

• Service Design
• Social Design
• Design for Policy
• +5 more

Jeff Schorey is the George B. Craig Jr. Professor and a full Professor in the Department of Biological Sciences at the University of Notre Dame, where he has been a faculty member since 2004. He currently serves as Director of the Integrated Biomedical Sciences (IBMS) graduate program and previously held leadership roles including Chair of the Institutional Animal Care and Use Committee (IACUC) and Associate Director of the Eck Institute for Global Health. His research focuses on the pathobiology of mycobacterial diseases, particularly Mycobacterium tuberculosis and M. avium . His work investigates the molecular interactions between mycobacteria and host macrophages, with a special emphasis on the role of exosomes in immune modulation, diagnostics, and vaccine development. He also explores novel antibiotic development in collaboration with chemists at Notre Dame and global partners. His recent publications reveal a strong trend in extracellular vesicle biology, host-pathogen signaling, and translational applications in TB diagnostics and treatment. The articles span immunology, microbiology, and molecular biology, with recurring themes in exosome function, RNA sensing, and antimicrobial development. George B. Craig Jr. Collegiate Professor Dr. Schorey has advised graduate students and leads an active research lab focused on mycobacterial pathogenesis. His work is supported by collaborations across disciplines and institutions, particularly in drug development and clinical translation. He has contributed significantly to understanding how exosomes can serve as both biomarkers and therapeutic tools. His lab employs cellular immunology, animal models, and clinical sample analysis to study mycobacterial infections. He leads the IBMS program, shaping graduate education in biomedical sciences at Notre Dame.

• Microbiology
• Immunology
• Infectious Diseases
• +9 more

Timo Minssen is Professor of Law at the University of Copenhagen (UCPH) and the Founding Director of UCPH's Center for Advanced Studies in Bioscience Innovation Law (CeBIL). He also holds affiliations as an LML Research Affiliate at the University of Cambridge and an Inter-CeBIL Research Affiliate at Harvard Law School's Petrie-Flom Centre. With extensive expertise in Intellectual Property, Competition, and Regulatory Law, Minssen focuses on the legal aspects of emerging health and life science technologies, including genome editing, big data, artificial intelligence, and quantum technology. His educational background includes a German law degree (Staatsexamen) from Georg-August-University in Göttingen, and Swedish biotech & IPR related LL.M., LL.Lic., and LL.D. degrees from Lund University and Uppsala University. His PhD thesis on the patentability of biopharmaceutical technology in the US & Europe received the prestigious Swedish King Oscar award. 2024: TUM Global Visiting Professor, Technical University of Munich (Germany) 2016: Visiting Research Fellow, University of Cambridge (UK) 2014: Visiting Research Fellow, University of Oxford (UK) 2013-14: Visiting Scholar, Harvard Law School (US) 2012: LL.D. - Doctor of Laws (Swedish "juris doktor"), EU/US patent law, Lund University, Sweden Minssen's research spans AI & Big Data in Health & Life Sciences, Sustainable and responsible innovation & tech transfer, Pharmaceutical-, Life Science- & Biotech Law, Comparative European & US Patent Law, Intellectual Property Law & Open Innovation, and EU Competition- & US Antitrust Law. His work addresses legal issues throughout the lifecycle of health and life science products and processes, from R&D regulation to technology transfer and commercialization. His extensive publication record includes 7 books and over 200 articles and book chapters published in leading journals such as Science, Nature Biotechnology, JAMA, and Harvard Business Review. His research has been featured in The Economist, Financial Times, and other major media outlets. Minssen's recent work shows a strong focus on AI regulation, quantum technology law, and data governance in health contexts, reflecting the evolving landscape of technology and law. Scientific Awards and Recognition King Oscar award for best Jur. Dr. thesis (2014) Jorcks Fonds Forsknings Pris (Jorck's Foundation Research Prize) (2017) Awapatent Research Prize (2009) Max Planck Research Scholarship (2005) Visiting Scholar appointments at Harvard Law School, University of Oxford, and University of Cambridge Recipient of a Novo Nordisk Foundation Grant for a "Collaborative Research Program in Biomedical Innovation Law" (2018) As an advisor, Minssen serves international organizations including the WHO, WIPO, and EU Commission. He has supervised numerous PhD students in areas including pharmaceutical law, biotechnology patents, and antimicrobial resistance. His current research projects include the Novo Nordisk Foundation's International Collaborative Bioscience Innovation & Law (Inter-CeBIL) Programme (50 million DKK), CLASSICA: EU Horizon Project on AI-assisted surgery, and AI@Care: Law and Ethics and Algorithmic Bias in Healthcare. Minssen leads the Center for Advanced Studies in Bioscience Innovation Law (CeBIL), which serves as a hub for interdisciplinary research on the intersection of law, technology, and innovation in the health and life sciences. The center collaborates with institutions worldwide to address pressing legal challenges in emerging technologies.

• Intellectual Property Law
• Competition Law
• Regulatory Law
• +4 more

Emie Yiannaka is a Professor in the Department of Agricultural Economics at the University of Nebraska-Lincoln, affiliated with the College of Agricultural Sciences and Natural Resources. Her research focuses on the economic impacts of new technologies and policies in the agri-food sector, including genetically modified products, food fraud, and consumer behavior. Ph.D. in Agricultural Economics, University of Saskatchewan (2002) M.Sc. in Agricultural and Resource Economics, Mediterranean Agronomic Institute at Chania, Greece (1996) M.A. in Agricultural Policy, Mediterranean Agronomic Institute at Chania, Greece (1995) B.Sc. in Agricultural Economics, Aristotle University of Thessaloniki, Greece (1994) Her research spans topics such as innovation economics, intellectual property strategies, consumer acceptance of food technologies, and the economic effects of corporate social responsibility. Recent work examines food fraud deterrence, information avoidance behavior, and ecosystem services valuation. She has published extensively in journals like Journal of Agricultural and Resource Economics , PLOS ONE , and American Journal of Agricultural Economics . Yiannaka has taught courses including Agricultural Marketing in Multinational Environments, Applied Welfare Economics, and Innovation Strategies. She has mentored numerous advisees, including Mavroutsikos C., Deka A., Britwum K., and Meerza S.I.A., who co-authored key publications on food fraud and consumer behavior.

• Agricultural Economics
• Agri-food Sector
• Innovation Economics
• +5 more

Professor Hak-Kim Chan of the Sydney Pharmacy School at the University of Sydney is a world-renowned expert in respiratory drug delivery, particularly pulmonary aerosols and inhalation therapies. With over 480 publications and 17,580+ Google Scholar citations, he has pioneered advancements in powder formulation , in silico modeling , and clinical applications of inhalation technologies. His work includes the development of FDA-approved diagnostics like Aridol™ (inhaled mannitol for asthma) and Bronchitol™ (for cystic fibrosis), and groundbreaking research on inhaled bacteriophage therapy to combat antibiotic-resistant respiratory infections. Education: BPharm (University Medal, 1983), PhD (1988), DSc (2009) from University of Sydney Professional Experience: Postdoc at University of Minnesota (1988–89), Scientist at Genentech Inc. (1992–95) Leadership: Executive Editor of Advanced Drug Delivery Reviews , Fellow of AAPS and RACI His research spans in vitro production methods, computational modeling of inhaler design, and in vivo imaging of aerosol deposition. Current projects focus on nanomedicine , phage therapy , and combating superbugs via inhalation routes. He has secured significant recognition for his work, including NHMRC case studies highlighting public health impacts. Professor Chan has supervised numerous researchers, including PhD student Grace YAU studying pulmonary probiotic delivery . His team's 10 patents (7 as first inventor) reflect practical innovations in dry powder inhalers , antimicrobial formulations , and drug stabilization technologies.

• Respiratory Drug Delivery
• Pulmonary Drug Delivery
• Inhalation Aerosols
• +5 more

Yousif Shamoo is the Ralph and Dorothy Looney Professor of BioSciences at Rice University, where he has been a faculty member since 1998. He previously served as Vice Provost for Research (2014-2022) and Director of the Institute of Biosciences and Bioengineering (2008-2014). He holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University (1988). His research focuses on combating multi-drug resistant bacteria through experimental evolution and biophysical approaches. Key interests include: Evolutionary trajectories of antibiotic resistance in pathogens like Enterococcus and Acinetobacter Biochemical basis of adaptation using microfluidics, genomics, and structural biology Discovery of novel antimicrobial strategies targeting cell membrane stress pathways Microbial interactions in spatially structured environments Publications emphasize antimicrobial resistance mechanisms, evolutionary biophysics, and microfluidic technology development. Recent work explores daptomycin resistance pathways ( LiaFSR ), membrane lipid signaling, and high-throughput evolution platforms. Awards & Honors: AAAS Fellow (2024) Ralph and Dorothy Looney Professorship (2020) George R. Brown Award for Excellence in Teaching (2015) George R. Brown Superior Teaching Award (4×, 2009 onward) ASM Distinguished Lecturer (2011-2013) He leads an active research group funded by NIH and DoD, advising 15+ graduate students. Current projects integrate synthetic biology with Streptomyces-derived drug discovery and microfluidic biosurveillance platforms.

• Antibiotic Resistance
• Bacterial Evolution
• Biophysics
• +3 more

Simon Sharpe is a Professor in the Department of Biochemistry at the University of Toronto and a Senior Scientist at The Hospital for Sick Children. His research focuses on the structural and dynamic properties of self-assembling proteins, particularly those involved in degenerative diseases, elastomeric proteins, and biological phase separation. The Sharpe Lab utilizes advanced biophysical techniques such as NMR spectroscopy, X-ray scattering, and electron microscopy to investigate these phenomena. BSc: Memorial University of Newfoundland (Cell Biology and Biochemistry, 1997) PhD: University of Western Ontario (Biochemistry, 2002) Postdoctoral Training: NIH (Solid-State NMR, 2002-2006) Research interests include: Protein self-assembly mechanisms Amyloid formation in neurodegenerative diseases Elastin and resilin biophysics Lipid-protein interactions Biological phase separation Structure-function relationships Lab members include Research Associate Dr. Sean Reichheld and PhD students James Otis, Asal Nady, and Robert Lu. The lab has dedicated access to 600 and 700 MHz NMR spectrometers and collaborates with SickKids facilities including the SBC Facility and Imaging Facility. Scientific awards: Canada Research Chair (2006-2016) Ontario Early Researcher Award (2010) Dr. Sharpe has taught courses including BCH374Y1 (Research Project in Biochemistry) and BCH425H (Structural Biology: Principles and Practice). His recent publications examine topics ranging from serum amyloid A structure to bacterial phase separation defenses, with methodologies combining solid-state NMR, fluorescence microscopy, and computational approaches.

• Biophysics
• Structural Biology
• Molecular Biophysics
• +9 more

Dr. Leon Barron is a Reader in Analytical & Environmental Sciences at the School of Public Health, Imperial College London. His expertise spans chemical contaminant analysis, wastewater epidemiology, and environmental forensics. He leads the Emerging Chemical Contaminants team within the Environmental Research Group, focusing on pharmaceuticals, PFAS, and illicit drugs. Education: BSc(Hons) in Analytical Science (2001), PhD in Analytical Chemistry (2005), and a Postgraduate Certificate in Academic Practice (2011). Previously held roles at King's College London as Lecturer (2009–2015) and Senior Lecturer (2015–2020). Research interests include trace environmental analysis (LC, GC, MS), chemical risk assessment, and wastewater-based epidemiology. Key projects include global drug use monitoring via sewage analysis and PFAS removal from drinking water. His work has produced over 100 peer-reviewed articles, with recent focus on PFAS accumulation, biochar filtration, and urban pollution source apportionment. Awards include Fellowships from Royal Society of Chemistry and Chartered Society of Forensic Sciences. Supervises PhD students on topics like pesticide exposure, opioid monitoring, and machine learning in ecotoxicology. Collaborates internationally via initiatives like the Sewage Analysis CORE Group and NIHR HPRU in Environmental Exposures.

• Environmental Chemistry
• Toxicology
• Analytical Chemistry
• +7 more

Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery and Development
• +13 more

Jennifer Curtis is a Full Professor in the School of Physics at Georgia Institute of Technology and serves as an ADVANCE Professor for the College of Sciences. Her research focuses on the physics of cell-cell and cell-extracellular matrix interactions, particularly within glycobiology and immunobiology contexts. Dr. Curtis earned her Ph.D. in Physics from the University of Chicago (2002) and her B.A. in Physics from Columbia University (1997). Her research interests span biophysics at interfaces, quantitative modeling of collective cellular interactions, cell mechanics, motility, adhesion, and the role of bulky sugars in tissue organization. Her laboratory investigates collective and single cell migration, immunophage therapy (combining immune cells with phages to combat bacterial infections), and molecular biophysics of hyaluronan synthase. Recent work demonstrates applications in soft materials, biomaterials, tissue engineering, and advanced characterization techniques. Analysis of her publication record reveals consistent focus on glyco-biophysics and cellular mechanics, with increasing emphasis on microbial communities and therapeutic applications. Her work bridges physics, biology, and engineering through interdisciplinary approaches. Honors include the NSF CAREER Award (2010), Georgia Tech College of Sciences Faculty Mentor Award (2015), and Cullen Peck Award (2020). She serves on the Biophysical Journal editorial board. Dr. Curtis actively mentors students through the Georgia Tech Physics REU program (which she directs) and collaborates with biologists, chemists, and materials scientists. Her laboratory maintains strong partnerships with institutions including Emory University and international collaborators. The Curtis Lab operates the Cell Physics Laboratory in the Molecular Science & Engineering Building, utilizing advanced techniques including holographic optical tweezers, thermochemical nanolithography, and single-molecule imaging to study cellular mechanics and polymer physics at biological interfaces.

• Biophysics
• Cell Mechanics
• Glycobiology
• +5 more

Dr. Megan Bergkessel is a Research Professor in Molecular Microbiology at the University of Dundee's School of Life Sciences. Her research focuses on understanding how bacteria like Pseudomonas aeruginosa regulate activities during growth arrest, particularly in resource-limited environments. This work addresses antibiotic tolerance mechanisms critical to chronic infections. Principal Investigator leading studies on non-growing bacterial physiology Recipient of a £900k UKRI Future Leaders Fellowship (2020) Expertise in antimicrobial resistance and microbial stress responses Current research explores regulatory pathways enabling protein synthesis in non-growing states, with implications for developing novel infection treatments. Supervises PhD projects investigating two-component signaling systems and environmental sensing in P. aeruginosa. Recognized for teaching excellence in Biological and Biomedical Sciences programs. PhD opportunities: Adaptive antimicrobial resistance mechanisms and environmental sensing roles Media commentary available via Corporate Communications

• Molecular Microbiology
• Antimicrobial Resistance
• Bacterial Physiology
• +3 more

Jessica Rosenholm is a Professor at the Faculty of Science and Engineering, Department of Pharmacy at Åbo Akademi University. Her research focuses on drug delivery systems, nanomedicine, and biomaterials engineering. She holds a D.Sc.(Tech.) and has authored over 200 publications. Key research areas include mesoporous silica nanoparticles, 3D bioprinting, and antimicrobial resistance solutions. Her work contributes to UN Sustainable Development Goals, particularly in advancing health technologies. Notable achievements include the Akzo Nobel Nordic Research Prize 2009 and the Knight, First Class, of the Order of the White Rose of Finland (2022). She leads projects like the MADNESS Centre of Excellence, exploring materials-driven solutions against antimicrobial resistance. Education: Doctor of Science (Technology) Research Interests: Nanoformulations, biomedical imaging, microfluidics, and tissue engineering. Recent articles highlight innovations in programmable nanocomposites for hearing loss treatment, microfluidic assembly of nanostructures, and 3D printing of drug delivery systems. Awards: ÅAU Chancellor’s Prize (2013), Forskarpriset ur Harry Elvings legat (2009) Grants: Projects funded by EU, Finnish Research Council, and Sigrid Jusélius Foundation. Labs/Teams: BioNanoMaterials group explores cutting-edge technologies like nanomedical agents and microfluidics. Current projects include the NAP4DIVE initiative for blood-brain barrier drug delivery.

• Drug Delivery Systems
• Nanomedicine
• Biomaterials Engineering
• +6 more